Waystar Weighs Strategic Options, Including Possible Sale

Healthcare software company Waystar is evaluating strategic alternatives, including a potential sale, sources familiar with the situation have disclosed. The company, which specializes in automating administrative tasks for hospitals and healthcare providers, has engaged investment bank Evercore to advise on its options. This move comes two years after Waystar went public on the New York Stock Exchange.

Market Challenges and Valuation Decline

Waystar's market valuation has recently declined to approximately $4.8 billion following a 24% drop in its share price this year. This downturn reflects a broader selloff in the software sector, as investors express concerns about the potential impact of emerging artificial intelligence technologies on traditional software business models. In July, analysts from Morgan Stanley noted that these AI advancements could disrupt the market, affecting investor confidence in software firms.

Initially, Waystar's strategy to position itself as a technology-focused company, rather than a labor-intensive service provider, attracted investor interest. This approach helped boost its share price from an initial $20 to a peak of $45 in 2025. However, recent market shifts have put pressure on the stock.

Background and Ownership

Waystar was formed through a merger between Zirmed and Navicure in 2017, both of which were involved in healthcare revenue management. Its major stakeholders include EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. These investors were instrumental in taking the company public in 2024. Currently, EQT holds a 13% stake, while CPPIB and BlackRock Institutional Trust Company own 10% and 8% respectively, according to data from LSEG.

Despite the current exploration of options, insiders caution that plans are still in the early stages and may not necessarily lead to a sale. Waystar, Evercore, EQT, and CPPIB have all declined to comment on the matter.

Future Prospects and Investor Interest

The potential sale process could serve as a barometer for investor interest in the software sector, which has been experiencing volatility. By exploring these strategic options, Waystar aims to assess the market's appetite for healthcare software companies amid the changing technological landscape.

If Waystar proceeds with a sale, it could mark a significant shift for the company, which has been publicly traded for just two years. The outcome of this exploration will likely influence the company's future direction and its positioning within the healthcare technology industry.